Xeltis
PrivateLast Round
Early Funding
Jul 28, 2026
Total Funding Raised
$223.02M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Xeltis is a medical device company that develops bioabsorbable heart valves and blood vessels aimed at promoting natural tissue restoration in cardiovascular therapy.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xeltis Comparables
Compare Xeltis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PECA Labs, Inc. | 85% | |
| VeriGraft | 81% | |
| Foldax Inc. | 81% |
Xeltis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jul 28, 2026 | ||||
| Debt | Dec 2, 2025 | ||||
| VC Round | Dec 2, 2025 | ||||
| Corporate Funding | Apr 8, 2025 | ||||
| Series D Extension | Aug 15, 2023 | ||||
Series D | Feb 21, 2023 |
Xeltis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series D Extension, VC Round, Corporate Funding |
| EQT Life Sciences | Series C, Early Funding, Series D Extension, VC Round, Series D, Series B Extension, Series B |
| Invest-NL | Early Funding, Series D Extension, VC Round, Series D |
| Ysios Capital | Series C, Series D |
| European Innovation Council | Early Funding |
| Horizon 3 Healthcare | Early Funding |
| VI Partners | Series C, Early Funding, Series D, Series B Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
$23.3M raised, led by Horizon 3 Healthcare.
- Apr 17, 2026
CMO interviewed at LSX World Congress in Lisbon.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
Xeltis is developing transformative implants through its Restorex platform, which regenerates a patient’s own tissue before being absorbed and leaving living, long-lasting vessels; its most advanced product under commercial development is aXess, an implantable blood vessel for hemodialysis access.
Xeltis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Xeltis's valuation, stock price, and market status.
Is Xeltis a public or private company?
Xeltis is a private company.
What is the current stock price of Xeltis?
Xeltis is a private company, so its shares have no public market price. Caplight tracks Xeltis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xeltis worth (valuation)?
Valuation information for Xeltis is not publicly available.
Can I buy Xeltis stock?
Xeltis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xeltis's last funding round?
Xeltis's most recent funding round was Early Funding on July 28, 2026.
Who are the main investors in Xeltis?
Key investors in Xeltis include European Innovation Council Fund, EQT Life Sciences, Invest-NL, Horizon 3 Healthcare, European Investment Bank Group.
Will Xeltis IPO soon?
No public IPO plans have been announced for Xeltis.
How can I track Xeltis secondary market activity?
Caplight tracks bids, offers, and trades in Xeltis's shares on secondary markets.